玻璃体腔注射康柏西普联合全视网膜激光光凝治疗不同分期增殖性糖尿病视网膜病变
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

国家自然科学基金资助项目(No.82101164); 山东省自然科学基金项目(No.ZR2020QH148,ZR2021MH074,ZR2021MH152); 泰山学者工程专项经费资助项目(No.tsqn202211344)


Effect of panretinal photocoagulation combined with intravitreal Conbercept in the treatment of proliferative diabetic retinopathy with different stages
Author:
Affiliation:

Fund Project:

National Natural Science Foundation of China(No.82101164); Natural Science Foundation of Shandong Province, China(No.ZR2020QH148, ZR2021MH074, ZR2021MH152); Taishan Scholar Foundation of Shandong Province(No.tsqn202211344)

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:评价玻璃体腔注射康柏西普联合全视网膜激光光凝(PRP)治疗不同分期增殖性糖尿病视网膜病变(PDR)的疗效。

    方法:回顾性病例研究。选取于2018-01/2020-06期间初次就诊于我院的PDR患者100例100眼,入选患者均行玻璃体腔注射康柏西普治疗,并在注药后1mo内进行PRP治疗。依据我国糖尿病视网膜病变临床诊疗指南,根据眼底荧光血管造影及眼底检查结果分为3组:A组早期PDR组34眼; B组高危PDR组43眼,C组纤维增生早期PDR组23眼。观察3组患者基线情况以及联合治疗后1、3、6mo和末次随访时的最佳矫正视力(BCVA)、黄斑中心厚度(CMT)、玻切手术率,视网膜脱离率。

    结果:本研究平均随访14.60±11.64mo(6-52mo)。患者平均年龄为54.22±9.32岁。治疗后行玻切手术患者15眼(15.0%),3组玻璃体切除率分别为2.9%(A组)、13.9%(B组)、34.7%(C组)。治疗后无视网膜脱离情况发生。末次随访较基线水平,3组患者治疗后BCVA和CMT值均有改善。

    结论:玻璃体腔注射康柏西普联合PRP治疗不同分期PDR是安全有效的,可有效提高患者视力,减轻视网膜水肿。

    Abstract:

    AIM: To investigate the effectiveness of panretinal photocoagulation(PRP)combined with intravitreal conbercept(IVC)for patients with different stages of proliferative diabetic retinopathy(PDR).

    METHODS: Retrospective study. The medical records for 100 patients(100 eyes)with PDR treated with PRP combined with IVC from January 2018 to June 2020 were reviewed, including 34 eyes with early PDR(group A), 43 with high-risk PDR(group B), and 23 with fibrovascular PDR(group C). The baseline information, best corrected visual acuity(BCVA), central macular thickness(CMT), the rate of vitrectomy and retinal detachment of the patients in the three groups at 1, 3, 6mo and the last follow-up after combination treatment were observed.

    RESULTS: The patients were followed up for 14.60±11.64mo(6-52mo), with a mean age of 54.22 ±9.32 years. We found 15 eyes(15.0%)who underwent vitrectomy after the combination treatment. The vitrectomy rates of the three groups were 2.9% in group A, 13.9% in group B, and 34.7% in group C. We found no instances of retinal detachment after the treatments. Most patients demonstrated improved BCVA and CMT values with the treatments.

    CONCLUSION: PRP combined with IVC is safe and effective in patients with different PDR stages.

    参考文献
    相似文献
    引证文献
引用本文

单田慧,俞嘉宣,刘春莉,等.玻璃体腔注射康柏西普联合全视网膜激光光凝治疗不同分期增殖性糖尿病视网膜病变.国际眼科杂志, 2023,23(8):1242-1249.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2023-01-16
  • 最后修改日期:2023-05-08
  • 录用日期:
  • 在线发布日期: 2023-07-25
  • 出版日期: